Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) announced financial results for Q4 2022 and updates on ongoing clinical trials. The company has commenced dosing patients in a Phase 2 trial of ELX-02 for Alport syndrome, showing an initial reduction in proteinuria in one patient. Topline results are anticipated in H1 2023, with expectations of progressing to a Phase 3 study. Eloxx also filed an IND application for ZKN-013 to treat recessive dystrophic epidermolysis bullosa (RDEB) and plans to develop it further for familial adenomatous polyposis (FAP). The company reported a net loss of $6.3 million for Q4 2022, down from $12.1 million a year prior, and had cash reserves of $19.2 million as of year-end.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the submission of an Investigational New Drug (IND) application for ZKN-013 aimed at treating recessive Dystrophic Epidermolysis Bullosa (RDEB) with nonsense mutations. Currently, no approved treatments exist for RDEB and junctional epidermolysis bullosa (JEB). Preclinical data demonstrated up to an 18-fold increase in functional COL VII protein levels, supporting ZKN-013's efficacy. Additionally, an IND for familial adenomatous polyposis (FAP) is anticipated in the first half of 2023. Eloxx's efforts leverage its novel TURBO-ZM™ technology platform to develop therapies for rare diseases.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced its participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 13, 2023, at 12:00 PM ET. A live webcast and replay of the presentation will be accessible on their website.
The company focuses on ribosomal RNA-targeted genetic therapies and is advancing its lead candidate, ELX-02, through Phase 2 clinical trials for treating Alport syndrome linked to nonsense mutations. Eloxx is also engaged in preclinical efforts targeting rare diseases, including specific cancers and kidney disorders. For more details, visit www.eloxxpharma.com.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the dosing of first patients in its Phase 2 study of ELX-02 for Alport syndrome targeting nonsense mutations. This disease lacks effective treatment options, and the trial aims to enroll up to eight patients, with dosing set for two months and follow-up for three months. Key endpoints include safety and reduction in proteinuria. Topline results are expected in the first half of 2023, with the company emphasizing the potential of ELX-02 based on previous preclinical data.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has initiated its Phase 2 clinical trial for ELX-02, targeting Alport syndrome in patients with nonsense mutations. The trial has commenced with the first patient enrollments, and topline results are anticipated in the first half of 2023. The trial aims to assess safety and efficacy primarily through proteinuria measurement in up to eight patients over a two-month period. Eloxx has highlighted the drug's potential in restoring collagen production, citing preclinical success and previous clinical activity, establishing a foundation for its development in this underserved patient population.